Slate Medicines Adds Mark W. Hahn to Its Board

Private biotech company Slate Medicines has appointed Mark W. Hahn, a seasoned life sciences executive with over two decades of experience, including as CFO at Verona Pharma during its successful FDA approval and $10 billion acquisition by Merck in 2025.

By Exec-Edge Thu, July 16, 2026 at 7:18 PM GMT+3 1 min read · Yahoo Finance · July 16, 2026, 16:18 UTC

Slate Medicines Adds Mark W. Hahn to Its Board

Tickers: $MRK

Topics: Biotech Leadership Change

Read the full article at Yahoo Finance

More World news

Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC
Chicago Fed President Austan Goolsbee Expresses Concern Over Persistent Inflation Trends Seeking Alpha · November 12, 2026, 16:33 UTC
Nvidia CEO Jensen Huang Ousted Amid Allegations of Personal Misconduct and National Security Concerns TechCrunch · November 12, 2026, 16:32 UTC
Pomerantz Law Firm Investigates Silvercorp Metals Inc. Following Production Shortfalls and Revenue Decline PR Newswire · November 12, 2026, 16:30 UTC
Cold Spring Harbor Laboratory Raises $6.5 Million at 21st Annual Double Helix Medals Dinner PR Newswire · November 12, 2026, 16:30 UTC
Deloitte Recognized as Leader in IDC MarketScape Worldwide Digital Identity Services Assessment PR Newswire · November 12, 2026, 16:30 UTC
SpaceX Announces $74 Billion Investment in AI Data Center Projects in Texas and Arizona Seeking Alpha · November 12, 2026, 16:25 UTC
Ofcom Fines Meta £450,000 Over Inaccurate WhatsApp Business Data Seeking Alpha · November 12, 2026, 16:25 UTC